In clinical trials, precision alone isn’t enough. Clients need clarity, confidence, and a team they can rely on. This article explains how Agilex delivers client-centric bioanalysis through tailored engagement, dedicated leads, and transparent collaboration.
Oligonucleotide therapeutics are transforming modern medicine, but analysing them is anything but simple. This article breaks down the three core challenges of oligonucleotide bioanalysis and the regulatory-ready LC-MS strategies required to generate reliable, submission-quality data.
Agilex Biolabs expands with a new Flow Cytometry Laboratory at QIMR Berghofer, boosting speed and precision in clinical research.
Contracted by the South Australian Government, Agilex Biolabs is deploying world-class science to sa...
Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new....
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the ris...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in c...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agi...
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development...
Research shows that Biotechnology companies have been facing significant challenges – with continu...
By Dr. Kurt Sales, CSO Introduction Immunological assays are essential in drug development, es...
By Dr. Kurt Sales, CSO Peripheral Blood Mononuclear Cells (PBMC) are critical for the pharmacodyn...
The Role of Peripheral Blood Mononuclear Cells (PBMCs) in Drug Discovery and Clinical Trials. By...
By Dr. Kurt Sales, CSO Oligonucleotides, including small interfering RNA (siRNA) and antisense ol...
By Dr. Kurt Sales, CSO In the high-stakes world of drug development, biotech companies face uniqu...
By Dr. Kurt Sales, CSO Liquid chromatography-mass spectrometry (LCMS) has become an indispensable...
By Dr. Kurt Sales, CSO Preclinical toxicology studies are an essential part of the drug developme...
By Dr. Kurt Sales, CSO Biomarkers are playing an increasingly important role in clinical studies...
by Dr. Kurt Sales, Chief Scientific Officer Liquid chromatography-tandem mass spectrometry (LC-MS...
An exclusive delegation coming from Australia - where leading drug development experts will converge...
Flow cytometry has become a powerful tool in the bioanalytical arsenal. In an era where pharmaceu...
Agilex has offered our clients small molecule solutions that lead to their success. Agilex Biolab...
For 3 decades, Agilex has supported biotech companies with CNS-targeted medicines. For almost 3 d...
Let's face it – we are an aging population throughout the world. More and more, we are seeing thes...
In molecular biology and pharmacology, small molecules are noted for their ability to quickly modula...
Applying Decades of Experience with an Eye on the Future of Small Molecule Development For decade...
Looking beyond the surface on the Complexity of Atopic Dermatitis Addressing inflammatory skin di...
We took some time to sit down and talk with Jason so you could get to know him a bit better... My...
We took some time to sit down and talk with Cameron so you could get to know him a bit better......
We took some time to sit down and talk with Dr Sales so you could get to know him a bit better......
Unraveling the Untapped Potential of Immuno-Oncology Technology Both the pace and varied methods...
A Quick Look at Agilex Biolabs' Expertise and Capabilities In the intricate landscape of drug dis...
Agilex Biolabs has extensive knowledge on small molecule development and pharmacokinetic services....
Agilex Biolabs integrates critical reagents services into comprehensive lifecycle management. The...
Agilex is pleased to introduce Mallory Jolly as our new Senior Business Development Director to the...
Agilex Demystifies the Rapidly Evolving Landscape of Drug Development Post-Covid, the field of bi...
作为 Healius 网络的一部分，Agilex Biolabs 公司继续进行全球扩张和企业发展，斯蒂芬-麦金太尔（Stephen McIntyre）被选为公司首席执行官。
ddPCR technology provides an opportunity to streamline research and development processes, saving ti...
Small and large molecule drug development often necessitates distinct analytical methodologies. Agil...
Agilex has extensive experience developing and validating like-binding assays for specific immune-on...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stand...
作为 Healius 网络的一部分，Agilex Biolabs 公司继续进行全球扩张和企业发展，斯蒂芬-麦金太尔（Stephen McIntyre）被选为公司首席执行官。
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduce...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technol...
by Holly Stefl, Chief Commercial Officer Agilex Biolabs is proud to introduce the West Coast of t...
by Dr. Kurt Sales, Chief Scientific Officer Pharmacokinetics is a key component in a drug develop...
by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, ad...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the C...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent....
支持澳大利亚临床试验的领先生物分析实验室 Agilex Biolabs 在南澳大利亚阿德莱德的 CMAX 临床研究机构五楼建立了首个卫星处理单位，配备了高度专业化的技术人员。
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials...
作为 Healius 网络的一部分，Agilex Biolabs 公司继续进行全球扩张和企业发展，斯蒂芬-麦金太尔（Stephen McIntyre）被选为公司首席执行官。
Rescue studies are a particular point of strength at Agilex Biolabs, where the bioanalytical experts are driven to solve challenges presented by what we call “the weird and wonderful”.
On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards.
支持澳大利亚临床试验的领先生物分析实验室 Agilex Biolabs 在南澳大利亚阿德莱德的 CMAX 临床研究机构五楼建立了首个卫星处理单位，配备了高度专业化的技术人员。
Agilex Biolabs has expanded its capacity to better serve the biotech, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility.
Circulating tumor DNA (ctDNA) is tumor-deriver fragmented DNA which originates either directly from the tumor or from circulating tumor cells.
Immunogenicity assessment of biotherapeutics is a regulatory requirement and key parameter for assessing the safety and efficacy of a drug candidate.
Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scient...
Learn how to improve Bioanalytical clinical outcomes by performing MetID characterisation. Leading...
Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory Agilex Biolabs...
Agilex Biolabs provides world-class toxicology services via its purpose-built GLP compliant facility...
This year, we at Agilex Biolabs celebrate our 25th year supporting Biotechs’ d...
Agilex Biolabs Pty Ltd has been purchased by one of Australia’s leading healthcare companies, Healius Limited
With increasingly novel drug development programs, meaningful collection of subject samples has never been more relevant. Don’t let potential analyte instability mislead your program as it gets underway, causing costly time delays
Agilex Biolabs Congratulates VGI Health Technology Limited for successful filing of a new PCT Patent Application on Transmucosal Delivery of Tocotrienols
With the integration of leading toxicology company TetraQ into Agilex Biolabs’ service offering, A...
Meet the Scientists series - Meer Dr Jason Geue, R& D Manager at Agilex Biolabs.
Agilex Biolabs, Australia’s most experienced and technologically advanced bioanalytical laboratory and the only biolab in the region with a dedicated toxicology unit, has been selected as a finalist for the Most Successful Early Phase Research (Preclinical & Phase I) category in the Citeline Awards 2021.
https://youtu.be/dnyLFRPLEJo...
Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials is showcasing its new $1.5m vaccine and immunobiology laboratory at BIO Asia Taiwan 2021. The facility, the most sophisticated in APAC, is designed for biotechs and pharma from around the world for advanced clinical research including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials announced for BIO Korea 2021 that their upgraded and expanded biolabs at the Australian headquarters is now complete.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
Inflammation is a complex biological process involving a host of resident and recruited immune cells which are mobilized to infiltrate tissues in response to invading pathogens. These immune cells boast elevated numbers and heightened activation as they churn out inflammatory mediators, which act in unison to coordinate and modulate the immune response.
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials is partnering with Endpoints News to share the latest on deconvoluting inflammation and immunology for clinical trials, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
Demand for APAC clinical trials is still on the rise as COVID numbers continue to fall across the region attracting biotechs wanting to restart stalled or paused clinical trials from around the globe. Indeed Australia recorded zero new cases in the past 25 days.
Are you a highly experienced Study Director with proven experience in developing and validating flow cytometry assays (immunophenotyping and receptor occupancy assays) and/or cell-based neutralising or mode of action assays in a regulatory environment?
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Register here (free)...
亚太地区领先的生物技术临床试验生物实验室 Agilex Biolabs 今天宣布推出名为 GALEXI™ 的客户门户网站。
Agilex Biolabs 技术团队与其微软合作伙伴一起加快了 GALEXI™ 的推出，以便在全球面临持续的 COVID 挑战时提供安全和增强的通信。
Agilex Biolabs 技术团队与其微软合作伙伴一起加快了 GALEXI™ 的推出，以便在全球面临持续的 COVID 挑战时提供安全和增强的通信。
澳大利亚最先进的 FDA 临床试验专业生物分析实验室 Agilex Biolabs 祝贺客户公司 Shasqi 宣布首次将点击化学应用于人体，并推出了公司的主要临床候选药物 SQ3370。Shasqi 是 Y Combinator 支持的第一家进入临床开发阶段的生物技术公司。
标题：在 Gyrolab 平台上开发和验证托西珠单抗一式和复式 PK 方法
澳大利亚最先进的临床试验生物分析专业实验室 Agilex Biolabs 祝贺客户 Zelira Therapeutics 完成药用大麻失眠症二期研究。
为什么澳大利亚是世界领先的早期阶段目的地--快速启动、无需 IND 以及政府支持退还近一半的试验费用 越来越多的申办者希望积极参与核心临床合作伙伴的选择，因为这关系到其临床研究的成败。
大家好。我是《端点新闻》（Endpoints News）的发行人阿萨兰-阿里夫（Arsalan Arif），很高兴担任今天的主持人。今天的网络研讨会由澳大利亚 Agilex 生物实验室赞助。我们的主题是：为什么澳大利亚是世界领先的早期阶段目的地--快速启动、无需 IND 以及政府支持退还近一半的试验费用。今天我请来了两位嘉宾。他们分别是 Agilex Biolabs 公司免疫测定部总监库尔特-萨尔斯（Kurt Sales）和 CMAX 临床研究公司首席执行官简-凯利（Jane Kelly）。
屡获殊荣的 Agilex Biolabs 是亚太地区领先的临床试验生物分析实验室，总部设在澳大利亚，该实验室已开发出世界上最精确的大麻素检测方法。
为一项试验召集主要的临床服务供应商可能是一个令人生畏的过程--尤其是当您要到海外重新启动试验或开始新的试验以弥补 COVID 延误时更是如此。
然而，澳大利亚拥有一批久经考验的顶级供应商，他们定期合作，充分参与，并与流程、彼此的要求和能力保持一致，因此简化的流程令人耳目一新。这使得生物技术公司在澳大利亚开展试验的过程更加顺畅、专业和快速。本网络研讨会将探讨将试验转移到澳大利亚如何比您想象的要容易得多。
然而，澳大利亚拥有一批久经考验的顶级供应商，他们定期合作，充分参与，并与流程、彼此的要求和能力保持一致，因此简化的流程令人耳目一新。这使得生物技术公司在澳大利亚开展试验的过程更加顺畅、专业和快速。本网络研讨会将探讨将试验转移到澳大利亚如何比您想象的要容易得多。
好了 大家好 All right.大家好。我是《端点新闻》（Endpoints News）的发行人阿萨兰-阿里夫（Arsalan Arif），很高兴担任今天的主持人。今天的网络研讨会由澳大利亚 Agilex Biolabs 公司赞助，我们的主题是 "澳大利亚的优势"--降低早期试验风险。今天和我一起的是 Agilex Biolabs 公司的 Kurt Sales 博士。他有一个大约 20 分钟的演讲，我们将在演讲后进行快速问答。现在有请库尔特-赛尔斯博士。
澳大利亚最大的临床试验专业生物分析实验室 Agilex Biolabs 与 Endpoints News 在 BIO Asia-Taiwan 2020 上推出了新的网络研讨会 "将试验转移到澳大利亚有多容易"。
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the Australian Advantage including the world’s most attractive rebate on clinical trials costs, at BIO Korea 2020.
The reality is, Australia has fantastic key opinion leaders, some great principal investigators that have been running clinical trials for decades. The CROs, RFA with FDA and EMA requirements. And in fact, our whole Australian service provision industry sets itself to that standard because ultimately that is the client base that Australia is servicing. Most CROs in Australia and service providers will be able to talk about situations where their data has been presented to the FDA or EMA with success.
https://youtu.be/WNdPGkdr9FA...
Video https://www.youtube.com/watch?v=sCUT8qtlRX4&feature=youtu.be...
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed PhD and NHMRC Fellow Patrick Hughes as R&D Manager Immunobiology.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory based in Australia, announced a raft of new pharmacodynamics services for biotech and pharma clients conducting preclinical and clinical trials in Asia, US, EU and Australia.
Australia-based Agilex Biolabs announced a broad range of new pharmacodynamics services for biopharma clients running preclinical and clinical trials in the U.S., Asia, European Union and Australia.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory based in Australia, announced a raft of new pharmacodynamics services for biotech and pharma clients conducting preclinical and clinical trials in Asia, US, EU and Australia.
One of the most important drug development start-up decisions is finding a centrally located bioanalytical laboratory that can support clinical research across all the study locations, and through pre-clinical then potentially for all Phases.
Quality control and consistency of sample management and analysis from early Phase onwards can make a real difference to quality of data and final outcomes.
Quality control and consistency of sample management and analysis from early Phase onwards can make a real difference to quality of data and final outcomes.
Australia-based Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for global clients conducting preclinical and clinical trials, announced at AusBiotech 2019 today it has been selected as a Top 10 Bioanalytical Services Provider by PharmaTech Outlook Magazine (Booth #523).
Boston, MA – Agilex Biolabs, the Asia Pacific’s leading bioanalytical laboratory, announced...
https://youtu.be/UrlJI-Y--k0...
Agilex Biolabs, Australia’s leading bioanalytical laboratory for global clients
conducting preclinical and clinical trials announced at DIA 2019 this week it will analyse more than 60,000 samples in 2019 (June 23-27 San Diego, CA) Booth 2006.
conducting preclinical and clinical trials announced at DIA 2019 this week it will analyse more than 60,000 samples in 2019 (June 23-27 San Diego, CA) Booth 2006.
